How does time-restricted eating work?
Time-restricted eating (TRE) is a chrono-nutrition intervention that confines daily energy intake to a defined window. This page outlines the mechanism as studied in randomised feeding trials and registered protocols, an
Time-restricted eating (TRE) is the formal term for an eating pattern that limits all daily energy intake to a defined window, typically 8 to 10 hours, without an explicit instruction to reduce calories. Synonyms in the literature include time-restricted feeding (TRF), chrono-nutrition, and, in one registered protocol, ChronoFeeding (CF) [7]. TRE is a behavioural and chronobiological intervention rather than a pharmacological class: it has no sequence, formula, or molecular weight, and it is defined operationally by the length of the eating window and the timing of that window relative to the circadian cycle. The comparator used across the registered trials below is a usual eating pattern (UEP), conventionally a 16-hour window, or standard weight-maintenance counselling [1][2].
The work centres on circadian regulation of nutrient handling — the alignment between feeding time and the endogenous clock that governs insulin sensitivity, substrate oxidation, and appetite-hormone secretion — rather than on a single receptor family.
Research Studies
TRE and appetite hormones in adults with obesity and prediabetes
The Time-Restricted Intake of Meals (TRIM) study was a 12-week randomised isocaloric and eucaloric feeding trial comparing 10-hour TRE with a 16-hour usual eating pattern in adults with obesity and either prediabetes or diet-controlled type 2 diabetes. A post hoc analysis examined eating behaviour, appetite hormones, and inflammatory markers. Participants completed the Three-Factor Eating Questionnaire (Restraint, Disinhibition, Hunger) and provided fasting blood samples for leptin, adiponectin, CRP, cortisol, and sRAGE at pre- and post-intervention timepoints [1]. Because the trial was isocaloric and eucaloric, any observed differences are attributable to the timing of intake rather than to energy restriction.
TRE and weight-loss maintenance in adults with overweight or obesity
A multi-centre, two-arm randomised controlled trial across six regions in China is testing whether a 10-hour daily TRE regimen prevents weight regain more effectively than standard weight-maintenance counselling alone. The population is overweight or obese adults who have recently achieved a short-term reduction of at least 5% of body weight. Both arms receive the same frequency and intensity of nutritional counselling; the only difference between groups is the eating window [2].
TRE, GLP-1 receptor agonists, and heart-healthy diet during androgen deprivation therapy
The phase II IMPACT-ADT trial compares TRE, GLP-1 receptor agonists (semaglutide and tirzepatide), and an American Heart Association heart-healthy diet intervention on cardiovascular and metabolic outcomes in prostate cancer patients undergoing androgen deprivation therapy. The rationale is that ADT-related metabolic changes — increased weight, body fat, and insulin resistance — raise cardiovascular risk in this population [3].
TRE combined with Urolithin A in adults with obesity
A registered study is testing whether daily Urolithin A (500 mg) for 6 months supports weight loss while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism in adults with a BMI above 30 during restricted eating. All participants receive the same structured nutrition and sleep programme; half receive Urolithin A and half a matching placebo [4]. Urolithin A is described in the protocol as a gut-derived, diet-related compound, and the background cites mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation as shared features of ageing and obesity [4].
TRE with health-coach support in adult survivors of childhood cancer
A registered study is examining whether motivational sessions, including regular calls with a trained health coach, combined with TRE achieve weight loss and lower cardiometabolic risk in adult survivors of childhood cancer, compared with the usual approach of reviewing educational materials and measuring weight once a month. The protocol states that the study will not provide treatment for any disease or cancer [5].
TRE over one year in adults with type 2 diabetes
A one-year intervention study is investigating the effectiveness of a TRE-based programme on glycaemic control, body weight and composition, cardiometabolic risk factors, and behaviour in individuals with overweight or obesity and type 2 diabetes [6].
TRE and chrono-nutrition in adults with ADHD
A randomised controlled pilot study of 60 adults with ADHD, aged 18 to 65, is testing a TRE-based intervention (ChronoFeeding) in participants with extended eating habits of more than 14 hours per day and sleep problems. Outcomes include quality of life, behaviour, sleep, and gut health, alongside biological markers such as microbiota from gut and saliva samples, inflammation, and oxidative stress. The protocol states that these markers will be studied in both humans and animal models [7].
TRE in polycystic ovarian syndrome
PCOS is associated with metabolic symptoms including hyperinsulinaemia, and TRE may reduce serum insulin and improve insulin resistance in this population. A randomised controlled crossover trial is testing the feasibility of an 18:6 eating protocol in PCOS by means of a real-world clinical intervention, with the primary determination being whether the protocol reduces insulin levels [8].
Comparison of registered TRE protocols
| Population | Eating window studied | Comparator | Primary focus |
|---|---|---|---|
| Adults with obesity and prediabetes or diet-controlled T2D [1] | 10 h | 16 h usual eating pattern | Appetite hormones, eating behaviour, inflammatory markers |
| Adults with overweight or obesity after ≥5% weight loss [2] | 10 h | Standard maintenance counselling | Weight regain |
| Prostate cancer patients on ADT [3] | TRE (phase II) | GLP-1 RA; AHA heart-healthy diet | Cardiovascular and metabolic outcomes |
| Adults with BMI >30 [4] | Restricted eating plus Urolithin A 500 mg | Placebo plus same lifestyle programme | Weight, muscle mass, mitochondrial and inflammatory markers |
| Adult survivors of childhood cancer [5] | TRE plus coaching | Educational materials, monthly weighing | Weight loss, cardiometabolic risk |
| Adults with overweight/obesity and T2D [6] | TRE-based, 1 year | Not specified in the record | Glycaemic control, body composition, behaviour |
| Adults with ADHD and extended eating habits [7] | ChronoFeeding | Randomised controlled pilot | Quality of life, behaviour, sleep, gut health, inflammation |
| PCOS [8] | 18:6 | Crossover | Serum insulin, insulin resistance |
If you are reading this for personal health reasons
The materials and compounds referenced on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or personal health advice of any kind. Anyone considering a compound or an eating intervention for themselves should speak to a licensed clinician.
Sources
- [1] Time-Restricted Eating on Appetite and Inflammation in Adults With Obesity and Prediabetes: A Randomized Feeding Study — https://pubmed.ncbi.nlm.nih.gov/42508996/
- [2] Time-Restricted Eating for Weight-Loss Maintenance — https://clinicaltrials.gov/study/NCT07163455
- [3] Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial — https://clinicaltrials.gov/study/NCT07202247
- [4] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating — https://clinicaltrials.gov/study/NCT07377136
- [5] A Study of Time-Restricted Eating in Childhood Cancer Survivors — https://clinicaltrials.gov/study/NCT07009288
- [6] Restricted Eating Time in the Treatment of Type 2 Diabetes — https://clinicaltrials.gov/study/NCT06152588
- [7] Developing Microbiome and Dietary Strategies Based on Chrono-nutrition for Targeting ADHD — https://clinicaltrials.gov/study/NCT07821060
- [8] Time-restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome — https://clinicaltrials.gov/study/NCT05126199